Researchers at the University of Cambridge have developed a new vaccine technology using artificial intelligence that could provide immunity against entire families of viruses. The team, led by Professor Jonathan Heeney, compared the approach to a 'master key' capable of unlocking protection against multiple virus variants. The technology aims to overcome the limitations of current vaccines, which target specific past strains and often fail to protect against new variants.

Heeney began developing the project after working in West Africa during the 2013–2016 Ebola outbreak, which caused over 11,300 deaths. Using early AI tools, his team analyzed extensive viral data to identify common and differing components that trigger immune responses, enabling broader protection. The AI-assisted universal Sarbeco coronavirus vaccine was tested on 39 volunteers under Southampton University Hospital supervision, with no significant safety concerns reported. Results were published in the Journal of Infection.

The vaccine, developed jointly by Cambridge scientists and biotechnology firm DIOSynVax, is now moving toward larger-scale trials. Heeney said the technology could help prevent future pandemics and represents a major conceptual shift in vaccine design.